Triple Agonist Retatrutide Leads Weight Loss Race But Dual Agonists Win on Safety
A Bayesian network meta-analysis of 19 RCTs finds retatrutide tops weight loss but dual agonists offer the best efficacy-safety balance.
Summary
A large network meta-analysis compared leading weight loss medications — liraglutide, semaglutide, tirzepatide, survodutide, and retatrutide — across nearly 30,000 adults with overweight or obesity. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, achieved the greatest likelihood of 15% or more body weight loss, but also carried the highest adverse event risk. Dual agonists like tirzepatide matched retatrutide on average weight loss (about 11 kg) with a more favorable safety profile. Standard GLP-1 medications like semaglutide averaged about 9 kg of weight loss. People with type 2 diabetes lost significantly less weight across all drug classes, while women and those with higher starting BMI tended to respond better.
Detailed Summary
Obesity remains one of the most pressing drivers of chronic disease and reduced healthspan, making effective pharmacological treatment a major clinical priority. As a new generation of weight loss medications reaches the market, clinicians and patients face a crowded landscape with limited head-to-head trial data. This network meta-analysis provides a rigorous comparative framework.
Researchers conducted a systematic review and Bayesian network meta-analysis (NMA) drawing on 19 randomized controlled trials and 29,506 adults with a BMI of 25 kg/m² or higher. Medications analyzed included liraglutide, semaglutide, survodutide, tirzepatide, and retatrutide, compared against placebo. The analysis assessed mean weight loss, proportions achieving 5%, 10%, and 15% weight reduction, waist circumference, BMI changes, and adverse events over at least 36 weeks.
Retatrutide — a triple agonist acting on GLP-1, GIP, and glucagon receptors — and dual agonists both achieved an average weight loss of approximately 11 kg, significantly outperforming GLP-1 receptor agonists alone at roughly 9 kg. Most strikingly, retatrutide showed an odds ratio of 54.6 for achieving 15% or greater weight loss, compared to 16.4 for dual agonists and 9.0 for GLP-1RAs. However, retatrutide also carried the highest adverse event burden. Type 2 diabetes status meaningfully blunted weight loss across drug classes — by 4.3 kg for GLP-1RAs and 5.0 kg for dual agonists. Female-dominant cohorts and those with higher baseline BMI showed enhanced treatment responses.
For clinicians, these findings reinforce a precision medicine approach: retatrutide may be best suited for patients prioritizing maximum weight reduction who can tolerate a higher side effect profile, while dual agonists represent a strong first-line option balancing efficacy and tolerability. Patients with type 2 diabetes may need adjusted expectations.
Key caveats include that retatrutide is not yet widely approved, and the NMA relied on aggregate trial-level data rather than individual patient data, limiting nuanced subgroup conclusions.
Key Findings
- Retatrutide achieves the highest rate of ≥15% weight loss (OR 54.6) but carries the greatest adverse event risk.
- Dual agonists (e.g., tirzepatide) match retatrutide on mean weight loss (~11 kg) with a better safety profile.
- GLP-1 receptor agonists alone average ~9 kg weight loss, significantly less than dual or triple agonists.
- Type 2 diabetes reduces weight loss by 4–5 kg across drug classes compared to normoglycemic patients.
- Women and individuals with higher baseline BMI respond better to these medications across drug classes.
Methodology
This was a systematic review and Bayesian network meta-analysis of 19 RCTs including 29,506 adults with overweight or obesity (BMI ≥25 kg/m²). Outcomes were assessed at ≥36 weeks and included mean weight loss, categorical weight loss thresholds, waist circumference, BMI, and adverse events. Subgroup and meta-regression analyses examined modifying factors including diabetes status, sex, age, and BMI.
Study Limitations
The summary is based on the abstract only, as the full text was not available; detailed methodology and individual drug-level safety data could not be fully evaluated. The NMA relied on trial-level aggregate data rather than individual patient data, which limits the precision of subgroup analyses. Retatrutide remains investigational in many jurisdictions, and longer-term safety and cardiovascular outcome data are still limited.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.